Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 14;10(2):594-606.
doi: 10.12998/wjcc.v10.i2.594.

Biologic therapy for Crohn's disease over the last 3 decades

Ji-Liang Shen  1 , Zheng Zhou  2 , Jia-Sheng Cao  1 , Bin Zhang  1 , Jia-Hao Hu  1 , Jia-Ying Li  2 , Xiao-Ming Liu  2 , Sarun Juengpanich  1 , Ming-Song Li  2 , Xu Feng  3
Affiliations

Biologic therapy for Crohn's disease over the last 3 decades

Ji-Liang Shen et al. World J Clin Cases. .

Abstract

Background: Despite the overload of publications on Crohn's disease (CD), no comprehensive analysis of biologic therapy for CD has been reported.

Aim: To determine knowledge gaps and identify areas of interest of biologic therapy for CD.

Methods: The top 100 highest-cited original articles were identified from January 1991 to December 2020 in the Clarivate Analytics Web of Science Core Collection database. We conducted a bibliometric analysis of biologic therapy for CD based on total citations, summarized the bibliographic information of the articles related to CD biologic therapy, and explored the research hotspots.

Results: The top 100 highest-cited original articles were identified with total citations ranging from 307 to 2978. The 2000s (Period II, n = 66) yielded the most influential original articles and saw the most dramatic growth. Among the top 10 countries, including 8 European countries and 2 North American countries, the United States (n = 37) and Belgium (n = 20) contributed the most publications. Among the top 10 institutions, the University Hospital Gasthuisberg in Belgium (n = 23), the University of Chicago in the United States (n = 20), and the Mayo Clinic in the United States (n = 17) published the most papers. Regarding authors, Rutgeerts P in Belgium (n = 32), Sandborn WJ in the United States (n = 23), and Feagan BG in Canada (n = 18) published the highest number of studies. The cooperation relationships between the United States and Europe were most frequent. Gastroenterology (impact factor = 22.682) published the most articles on biologic therapy for CD (n = 32) with 17654 total citations. Anti-tumor necrosis factor biologics and monoclonal antibodies were the most studied topics.

Conclusion: The bibliometric analysis emphasized the key contributions to the development of the specialized field. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.

Keywords: Bibliometric analysis; Biologic therapy; Crohn’s disease; Insight; Most influential.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Growth curve of the top 100 highest-cited original articles.
Figure 2
Figure 2
Number of the top 100 highest-cited original articles by country.
Figure 3
Figure 3
Cooperation relationships among all countries. UK: United Kingdom; USA: United States of America.
Figure 4
Figure 4
Cooperation relationships of institutions that have co-published more than three top-cited articles.
Figure 5
Figure 5
Cooperation relationships of authors that have co-published more than three top-cited articles.
Figure 6
Figure 6
Treemap of keywords of the top 100 highest-cited original articles.
Figure 7
Figure 7
Cluster analysis of keywords that appeared more than seven times.
See this image and copyright information in PMC

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741–1755. - PubMed
    1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–297. - PubMed
    1. Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol. 2021;12:207–213. - PMC - PubMed
    1. Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015:CD000067. - PMC - PubMed
    1. McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2014:CD003459. - PMC - PubMed